Targeting CXCR4 with [ 68 Ga]Pentixafor: a suitable theranostic approach in pleural mesothelioma?

Constantin Lapa; Stefan Kircher; Andreas Schirbel; Andreas Rosenwald; Saskia Kropf; Theo Pelzer; Thorsten Walles; Andreas K. Buck; Wolfgang A. Weber; Hans-Juergen Wester; Ken Herrmann; Katharina Lückerath

doi:10.18632/oncotarget.18235

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Targeting CXCR4 with [⁶⁸Ga]Pentixafor: a suitable theranostic approach in pleural mesothelioma?

Constantin Lapa _, Stefan Kircher, Andreas Schirbel, Andreas Rosenwald, Saskia Kropf, Theo Pelzer, Thorsten Walles, Andreas K. Buck, Wolfgang A. Weber, Hans-Juergen Wester, Ken Herrmann and Katharina Lückerath

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2017; 8:96732-96737. https://doi.org/10.18632/oncotarget.18235

Metrics: PDF 2276 views | HTML 3275 views | ?

Abstract

Constantin Lapa1, Stefan Kircher2, Andreas Schirbel1, Andreas Rosenwald2, Saskia Kropf3, Theo Pelzer4, Thorsten Walles5, Andreas K. Buck1, Wolfgang A. Weber6, Hans-Juergen Wester7, Ken Herrmann1,8 and Katharina Lückerath1

1Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, Germany

2Institute of Pathology, University of Würzburg, Comprehensive Cancer Center Mainfranken (CCCMF), Würzburg, Germany

3Scintomics GmbH, Fürstenfeldbruck, Germany

4Department of Internal Medicine I, Division of Pulmonology, Universitätsklinikum Würzburg, Würzburg, Germany

5Department of Thoracic Surgery, University Hospital Magdeburg, Magdeburg, Germany

6Molecular Imaging and Therapy Service, Memorial Sloan-Kettering Cancer Center and Weill-Cornell Medical College, New York, New York, USA

7Pharmaceutical Radiochemistry, Technische Universität München, Munich, Germany

8Department of Nuclear Medicine, University Hospital Essen, Essen, Germany

Correspondence to:

Constantin Lapa, email: [email protected]

Keywords: PET, CXCR4, [⁶⁸Ga] pentixafor, pleural mesothelioma, theranostics

Received: March 29, 2017 Accepted: May 15, 2017 Published: May 27, 2017

ABSTRACT

C-X-C motif chemokine receptor 4 (CXCR4) is a key factor for tumor growth and metastasis in several types of human cancer. This study investigated the feasibility of CXCR4-directed imaging with positron emission tomography/computed tomography (PET/CT) using [⁶⁸Ga]Pentixafor in malignant pleural mesothelioma.

Six patients with pleural mesothelioma underwent [⁶⁸Ga]Pentixafor-PET/CT. 2′-[¹⁸F]fluoro-2′-deoxy-D-glucose ([¹⁸F]FDG)-PET/CT (4/6 patients) and immunohistochemistry obtained from biopsy or surgery (all) served as standards of reference. Additionally, 9 surgical mesothelioma samples were available for histological work-up.

Whereas [¹⁸F]FDG-PET depicted active lesions in all patients, [⁶⁸Ga]Pentixafor-PET/CT recorded physiologic tracer distribution and none of the 6 patients presented [⁶⁸Ga]Pentixafor-positive lesions. This finding paralleled results of immunohistochemistry which also could not identify relevant CXCR4 surface expression in the samples analyzed.

In contrast to past reports, our data suggest widely absence of CXCR4 expression in pleural mesothelioma. Hence, robust cell surface expression should be confirmed prior to targeting this chemokine receptor for diagnosis and/or therapy.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 18235

Publication Alerts

Research Papers:

Targeting CXCR4 with [68Ga]Pentixafor: a suitable theranostic approach in pleural mesothelioma?

Abstract

Targeting CXCR4 with [⁶⁸Ga]Pentixafor: a suitable theranostic approach in pleural mesothelioma?